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Purpose: Brucellosis is a multi-systemic infection that is endemic in some parts of the world. The 
purpose of this study was to examine the epidemiology as well as the clinical and haematological 
characteristics, complications, and treatment outcome of patients with brucellosis at the King Fahd 
Hospital of the University Alkhobar, Saudi Arabia.  
Methods: A descriptive case assessment of all adult patients (aged 13 years and above) with 
brucellosis over a period of 10 years between 1998 and 2007 was undertaken.  
Results: The diagnosis of brucellosis in 84 patients was made by clinical findings, positive agglutination 
titre, and/or the isolation of Brucella species. The number of patients with brucellosis presenting at our 
hospital reduced over the study period, with a much smaller proportion of cases occurring after the year 
2000. Most of the patients had fever (73%) and musculoskeletal symptoms (64%). Splenomegaly was 
recorded in 13% and hepatomegaly in 11% of patients. Seven patients (8%) had epididymo-orchitis. 
Two patients presented with fever of unknown origin with negative serology and only bone marrow 
culture was positive for Brucella mellitensis. Two patients presented with menstrual associated recurrent 
fever. One previously healthy patient presented with jaundice and spontaneous peritonitis. No 
therapeutic failure was observed but relapse occurred in six patients (7%). None of the patients who 
received streptomycin or ciprofloxacin as part of their antibiotic regimen had a relapse. 
Conclusion: Brucellosis has a wide range of clinical manifestations. Although the number of patients 
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Brucellosis is a disease of domestic and wild 
animals that can be transmitted to humans 
(zoonosis). The disease exists worldwide, 
particularly in the Mediterranean basin, the 
Arabian Peninsula, the Indian subcontinent, 
and in parts of Mexico and Central and South 
America
1
. Consumption of contaminated 
foods and occupational contact remain the 




may present with protean clinical
 
manifestations that require broad differential 
diagnosis, including
 






infection that can affect any organ in
 
the 
body¹. The onset of disease is insidious in 
approximately half of all cases. It is 
characterized by several somatic complaints 
such as fever, sweats, anorexia, and weight 
loss. By contrast, there can be few abnormal 
physical findings. Occasionally, symptoms 
related to a single organ predominate. The 
aim of this study was to examine the 
epidemiological features, clinical and 
haematological characteristics, 
complications, and treatment outcomes of 
brucellosis in an endemic region.  
 
PATIENTS AND METHODS 
 
Study population  
 
Between 1998 and 2007, a descriptive case 
assessment of 84 adult patients with 
brucellosis presented to King Fahd Hospital 
of the University, Alkhobar, in a longitudinal 
prospective study. The university hospital is a 
secondary–tertiary care hospital in the 
Eastern Province of Saudi Arabia. 
 
Diagnostic criteria  
 
The diagnosis of brucellosis was based on 
the clinical findings characteristic of the 
disease and on either positive cultures that 
tested for Brucella species or a titre of ≥ 1: 
160 antibodies by tube agglutination. 
Complete blood count, sedimentation rate, 
liver function tests, and in some patients 
detection of immunoglobulin (IgM and IgG) 
antibodies by ELISA were also performed.  
 
Treatment and outcome  
 
Various treatment combinations of anti-
Brucella antimicrobials (streptomycin, 
doxycycline, co-trimoxazole, rifampicin, 
ciprofloxacin) were used, depending on the 
patient’s age and pregnancy status. The 
mean follow-up period was one year, 
although this was not possible for all patients 
because of the nomadic nature of the patient 
population. Relapse was defined as an initial 
improvement followed by reappearance of 
symptoms and signs during the treatment 
period or within 2 months of discontinuation 
of treatment. A cure was defined as no 
recurrence of symptoms and signs during the 




A total of 84 patients were diagnosed with 
brucellosis during the 10-year study. The 
number of patients with brucellosis reduced 
during the study period, with a much smaller 
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Fig.1: The distribution of Brucella cases between 
1998 and 2007 
 
The median age of patients was 32±9 years 
(range: 13–81 years). Males were more often 
affected than females and the male-to-female 
ratio was 3:1. Of the 84 patients, two 
presented with a relapse, while the other 82 
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were diagnosed with brucellosis for the first 
time. Fifty four patients (64%) gave history of 
contact with animals, sixteen patients (19%) 
gave history of drinking raw milk, five patients 
(6%) were involved in slaughtering animals 
particularly during Hajj season, three patients 
(4%) were laboratory workers, and six 
patients (7%) denied any risk factors for 
acquiring brucellosis. The occupations of the 
patients varied from farmers (21 males and 2 
females), Sheppard (12 males, and 1 
female), students (8 males and 4 females), 
teachers (6 males and 3 female), laboratory 
workers (2 males, and 1 female), engineer (I 
male), housemaid (1 female), housewives (18  
females), and unemployed (4 males).  
 
The clinical characteristics of the 84 patients 
with brucellosis are described in Table 1. A 
history of fever was obtained from 95% of 
patients, but it was positive in 73% of 
patients. A substantial number of patients 
(64%) developed arthritis or arthralgia. 
Splenomegaly was recorded in 13 (16%) and 
hepatomegaly in 9 (11%) patients. Two 
patients presented with fever of unknown 
origin with negative serology and only bone 
marrow culture was positive for Brucella 
mellitensis. Two patients presented with 
recurrent fever associated with menstruation.  
 
 
Table 1: Clinical characteristics and laboratory findings of 84 patients with brucellosis 
 
Symptom/sign Number of 
patients (%) 
Laboratory findings Number of 
patients (%) 
Tmax (axillary) 
 ≥39 °C 
 ≥37.5 °C <39 °C 








 (hemoglobin concentration <11.5 g/dL
 
in females and <13.5
 
g/dL in males) 
30 (36) 







Hepatomegaly 9 (11) Leukopenia (<4500 mm
−3
 ) 5 (6) 
Lymphadenitis 11 (13) Leukocytosis (>11,000 mm
−3
 ) 5 (6) 
Splenomegaly 13 (16) Lymphocytosis (>2500 mm
−3
 ) 50 (60) 
Fever of unknown origin 2 (2) Pancytopenia 1 (1) 
Epididymo-orchitis  7 (8) ESR (mm/h), median 35 
Endocarditis  1 (1) Increased AST and/or ALT  24 (29) 
Abortion  1 (1) Increased
 
GGT and alkaline 
phosphatase 
31 (37) 
Neurobrucellosis 1 (1) SAT(titer, ≥ 1 : 160) 80 (95) 









Positive culture for Brucella species 
Blood cultures 
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One previously healthy patient presented with 
jaundice and spontaneous peritonitis. The 
diagnosis was confirmed after isolating 
Brucella melitensis from blood and by 
complete resolution of symptoms with 
treatment. Eleven patients (13%) presented 
with generalized lymphadenopathy. Seven 
patients (8%) had epididymo-orchitis. 
Neurological and cardiac involvement was 
infrequent. One patient had meningitis and 




Erythrocyte sedimentation rate (ESR) was 
measured in all patients and it ranged from 4 
to 110 mm/hour (median 35 mm/hour). Thirty 





in females and <13.5
 
g/dL in males). Five patients had leukocytosis 
(>10,500 white blood cells [WBCs]/mm
3
), and 




). Lymphocytosis was seen in 50 






Twenty-four (29%) patients had slight-to-
moderately increased serum hepatic 
transaminase
 


























antibodies to Brucella (titre, ≥ 
1: 160). Cultures of specimens
 
from 33 (39%) 
of the 84 patients
 
were positive for Brucella 
species, thirty-one were isolated from blood 
samples, and two from bone marrow 
aspirates. Only 18 of the 33 Brucella isolates 
were speciated; this was because some 
isolates died, some specimens were 
discarded, or laboratory reagents were not 
available. Of these 18 isolates, twelve (67%) 
were B. melitensis and six (33%) were 
Brucella abortus. Antimicrobial susceptibility 
testing was carried out on 33 isolates. The 
number of Brucella isolates with antimicrobial 
resistance was as follows: 12 (36%) were 
resistant to co-trimoxazole; 6 (18%) were 
resistant to rifampicin; all isolates were 





performed to test for IgM and IgG 
antibodies in 28 patients, and only 18 (64%) 
were positive for IgM or IgG antibodies. A 
positive result was noted in 8 of 23 patients 
(34%) for culture-confirmed brucellosis.  
 
Treatment and rate of relapse 
 
Treatment regimens for the 84 patients 
consisted of combinations of two or three 
agents: streptomycin plus doxycycline (18%); 
doxycycline plus rifampicin (18%); doxycycline 
plus co-trimoxazole (12%); rifampicin plus co-
trimoxazole (2%); doxycycline plus 
ciprofloxacin (31%); and streptomycin plus 
doxycycline plus ciprofloxacin (19%). 
Streptomycin was administered for 15 days. 
Treatment with other antimicrobial agents 
varied according to clinical response and the 
development of complications (mainly 
arthritis). Spondylitis is recognized as the 
most common and one of the most debilitating 
forms of focal brucellosis and there is no 
consensus on the best therapeutic regimens, 
so we chose triple therapy (doxycycline, 
streptomycin, and ciprofloxacin) to treat 
patients with Brucella spondylitis. 
 
A total of 61 patients (73%) had long-term 
follow-up (12 months). Six patients (7%) 
suffered a relapse after completion of therapy 
with no osteoarticular or nervous system 
involvement. Three of these six patients had 
received doxycycline and co-trimoxazole. 
Isolates from two patients were found to be 
resistant to co-trimoxazole and the isolate 
from the third patient failed to grow. Three 
patients relapsed after receiving doxycycline 
and rifampicin. Blood cultures of both of these 
patients tested negative for Brucella. None of 
the patients who received streptomycin or 
ciprofloxacin in combination with doxycycline 
suffered a relapse (Table 2).  
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Table 2: Treatment and outcome for 84 patients with brucellosis 
 
Treatment Patients (%) Relapse rate (%) Cure rate (%) 
Dox + Rif 15 (18) 3 (13) 13 (87) 
Dox + Stm 15 (18) 0 15 (100) 
Dox + Cipro 26 (31) 0 26 (100) 
Dox + TMP-SMZ 10 (12) 3 (30) 7 (70) 
TMP-SMZ+ Rif 2 (2) 0 2 (100) 
Dox + Stm+ Cipro 16 (19) 0 16 (100) 
Total 84 (100) 6 (7) 78 (93) 
 
Note: The proportion of patients (%) receiving each regimen are shown; Dox – doxycycline; Rif – rifampin; 




Brucella is one of the world's main zoonotic 
pathogens, and is responsible for enormous 
economic losses, as well as considerable 
human morbidity in endemic areas. 
Brucellosis has been present for thousands of 





even in the most developed countries
2-4, 
.It is 
well known to have a
 
high prevalence in 
certain geographic areas, such as the 
Mediterranean basin, the Arabian Peninsula, 








unpasteurized animal-milk products, by direct
 
contact with infected animal parts (such as the 
placenta by
 
inoculation through ruptures of 
skin and mucous membranes),
 
and through 
the inhalation of infected aerosolized particles. 









The number of patients with brucellosis in our 
hospital reduced over the 10-year study 
period, with a much smaller proportion of 
cases occurring after 2000. This is due to the 
concerted efforts of   public health measures 
such as public education, milk pasteurization, 
and livestock immunization. In addition, 
increased awareness of the disease among 
physicians, improved laboratory diagnosis, 
and treatment of cases by primary care 





Human brucellosis is traditionally described as 
a disease of
 
protean manifestations, and the 
demographic
 





study emphasize the wide and 
unexpected spectrum of this disease. The 
characteristics of fever vary and can
 
be 
spiking and accompanied by rigors,
 
or may be 




Dissemination via the bloodstream can result 
in involvement of almost any organ and the 
clinical presentation can be misleading and 
cases in which gastrointestinal, respiratory, 
dermal, or neurological manifestations 
predominate are not uncommon
6-10
. However 
neurological or cardiovascular manifestation 
were rare in our patients . The results of 
physical examinations are often nonspecific, 
although
 
lymphadenopathy, hepatomegaly, or 
splenomegaly is often present. Hepatomegaly 
was observed in 9% of cases, whereas 
splenomegaly and lymphadenopathy were 
present in 13% of cases. 
 
Osteoarticular disease is the most common 
complication
 
of brucellosis, and was reported 
in 64% of patients in our study. There are 
three distinct forms: peripheral
 
arthritis, 
sacroilitis, and spondylitis. The reproductive 
system is the second most common site of 
focal
 
brucellosis. Brucellosis can present as 
epididymo-orchitis in
 
men and is often difficult 







during pregnancy is associated 
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with a substantial risk of spontaneous 
abortion
12
. We diagnosed epididymo-orchitis 
in seven patients, and one patient had an 
abortion.  
 
Hepatitis is common, usually manifesting as 
mild transaminasemia
13,14
. In our study 29% of 
patients had increased enzyme 
concentrations (ALT, AST). Jaundice is 
usually rare and only one of the patients in our 
study presented with jaundice, together with 
spontaneous peritonitis. The patient had no 
underlying condition such as chronic liver 
disease, congestive heart failure, nor was she 
on peritoneal dialysis. Brucellosis is a rare 
cause of bacterial peritonitis. Few cases have 
been reported, and most were associated with 
chronic liver disease
15
. The other patients had 
underlying conditions such as ascites caused 
by congestive heart failure
15
and in patients 
undergoing CAPD
16
. Our patient had complete 
resolution of symptoms with treatment. Two 
patients presented with menstrual associated 
recurrent fever. Although brucellosis is known 
to cause recurrent fever, the association with 
menstrual cycle to my knowledge has never 




test results are usually
 
mild 
and nonspecific. Changes in blood count are 
often due to mild leukopaenia and
 
relative 
lymphocytosis, together with mild anaemia 
and thrombocytopaenia. The most common 
haematological manifestations in our study 
were anaemia, lymphocytosis, and moderate 
increases in the sedimentation rate. In our 
study, one patient presented with 
pancytopenia. Pancytopaenia in brucellosis is 
multifactorial and has been attributed
 
to 
hypersplenism and bone marrow involvement.  
 
The absolute diagnosis of brucellosis requires 
isolation of
 
the bacterium from blood or tissue 
samples, or the combination of clinical 
symptoms and positive serology. The 
sensitivity
 
of blood culture varies, depending 
on individual laboratory practices and how the 
cultures are obtained. Positive blood cultures 
are found in 15
 
to 70% of patients with 
brucellosis
17
. In our study, positive cultures 
were obtained from 37% of blood and 2% of 
bone marrow samples of patients with 
brucellosis. Prior use of antibiotics is 
associated with reduced incidence of positive 
blood cultures but does not affect bone 
marrow culture. In two cases, patients had 
positive bone marrow cultures despite all 
other negative diagnostic tests for Brucella. A 
bone marrow culture is recommended for 
patients with fever of unknown origin, negative 
serology, and unexplained joint or 


















of antibodies to Brucella of ≥ 
1: 160 [standard tube
 
agglutination test] or ≥ 
1: 320 [Coombs' test]) are common, although 
low titers, determined by standard tube
 







cases patients with brucellosis can have 
positive blood
 
cultures but negative 
serology
20
. Two of the patients in our study 
with Brucella bacteremia had negative 
serology on repeated occasions. More 
recently, the Brucella enzyme-linked 
immunosorbent assay (ELISA) test has been 
introduced into clinical laboratories for the 
diagnosis of brucellosis. The ELISA test is 
reported to be rapid, highly sensitive, and 
specific for detecting the Brucella-specific IgG, 
IgM, and IgA antibodies in blood and 
cerebrospinal fluid
21
. In our study, in patients 
with Brucella bacteremia the sensitivity of the 
ELISA IgM or IgG tests were lower than the 
sensitivity of the standard tube agglutination 





The successful treatment of brucellosis 
requires prolonged chemotherapy regimen 
with a combination of antibiotics. In 1986, the 
World Health Organization issued guidelines 
for
 






involved doxycycline for six weeks and
 
in 
combination with either streptomycin for two to 
three weeks
 
or rifampin for six weeks. Both 
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combination regimens are the most popular
 










of streptomycin requires either hospital
 
admission or an adequate health care network
 
— both of which are often absent from areas 
of endemic disease.
 
On the other hand, the 
use of rifampin in areas in which brucellosis
 
is 
endemic, and where tuberculosis is also 
usually endemic, raises
 
concerns about the 
development of community resistance to 
rifampin. Al –Hajjaj et al documented 
worsening resistance in the Riyadh Region 
between 1986 and 1997 for both rifampicin 
and streptomycin
25
. The likely culprits are poor 
compliance and the wide use of rifampin and 
streptomycin for the treatment of brucellosis 
and other conditions.  
 








quinolones. A recent meta-analysis of the 
efficacy of various combinations
 
to treat 
spondylitis advocated treatment for at least
 






preliminary results indicate that quinolones 
may be cost-effective in spondylitis
26
. In this 
study, patients received various 
chemotherapy regimens. The duration of 
therapy was based on the level of organ 
involvement. No therapeutic failure was 
observed with any of the regimens, but the 
relapse rate was 7%. None of the patients 
who received streptomycin or ciprofloxacin in 
combination with doxycycline had a relapse. A 
regimen of doxycycline and ciprofloxacin is 
significantly more expensive than the 
traditional regimens. However, when the 
protracted duration of other treatment 
regimens, the economic impact of the residual 
damage and the economic consequences are 
considered, the combination of doxycycline 
and ciprofloxacin may prove cost-effective.  
CONCLUSION 
 
The clinical presentations among our patients 
emphasize the wide and unexpected 
spectrum of this disease. Timely diagnosis 
and treatment of patients with brucellosis 
require clinical awareness of the full spectrum 
of signs and symptoms associated with 
brucellosis, as delay in treatment can result in 
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